ATOS is the ticker symbol for ATOSSA THERAPEUTICS, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ATOS with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ATOS a good stock to buy?

ATOS is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/ATOS.

Where does 13F Pro source ATOS data?

All ATOSSA THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ATOSSA THERAPEUTICS, INC. files with the SEC under CIK 1488039. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

ATOSSA THERAPEUTICS, INC.(ATOS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ATOSSA THERAPEUTICS, INC. (ATOS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ATOS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), ATOSSA THERAPEUTICS, INC. reports net income of $-8.5M, free cash flow of $-9.6M. Top institutional holders of ATOS by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, AMERIPRISE FINANCIAL, BlackRock, based on the most recent SEC filings. ATOS trades on the Nasdaq exchange and files with the SEC under CIK 1488039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ATOSSA THERAPEUTICS, INC. directly from SEC EDGAR.

Net Income

$-8.5M

Free Cash Flow

$-9.6M

ATOS key financials by period

ATOSSA THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2015	10-K/A	$1.8K	$-15.8M	—
FY 2014	10-K	$40.1K	$-14.7M	—
FY 2013	10-K	$1.1M	$-20.5M	—
FY 2012	10-K	$483.3K	$-9.7M	—
FY 2011	10-K	$1.5K	$-3.4M	—

Institutions holding ATOS

Institutional investors reporting a position in ATOSSA THERAPEUTICS, INC. on SEC Form 13F.
Institution	Shares	Value	Reported
VANGUARD CAPITAL MANAGEMENT	361,747	$698.2K	2026-06-30
AMERIPRISE FINANCIAL	258,234	$498.4K	2026-06-30
BlackRock	164,358	$317.2K	2026-06-30
RENAISSANCE TECHNOLOGIES	132,043	$254.8K	2026-06-30
GEODE CAPITAL MANAGEMENT	92,382	$178.3K	2026-06-30
UBS Group AG	82,620	$159.5K	2026-06-30
JANE STREET GROUP	56,602	$109.2K	2026-06-30
VANGUARD FIDUCIARY	52,583	$101.5K	2026-06-30
MILLENNIUM MANAGEMENT	46,508	$89.8K	2026-06-30
SIMPLEX TRADING	48,300	$89.0K	2026-06-30

SEC EDGAR: CIK 1488039 →

ATOSSA THERAPEUTICS, INC.

ATOS

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.